DuChemBio said it has expanded its partnership with Cyclotek, Australia’s leading PET radiopharmaceutical company, to accelerate market entry into India and Southeast Asia.

The companies signed an exclusive licensing agreement covering the manufacturing and commercialization of DuChemBio’s Parkinson’s disease diagnostic agent 18F-FP-CIT across new territories.

Under the deal, Cyclotek will obtain exclusive rights to produce, distribute, and commercialize 18F-FP-CIT in India, Singapore, Malaysia, Thailand, Indonesia, and Vietnam, extending its reach beyond Australia and New Zealand.

The company will lead regulatory filings in each market, build local manufacturing capacity, and work with regional partners to bring the tracer to patients.

18F-FP-CIT is the first and only fluorine-18 labeled PET radiopharmaceutical that enables quantitative measurement of dopamine transporter (DAT) density in the striatum of the brain. Compared with traditional SPECT imaging, it offers higher resolution and accuracy, making it a valuable tool for the early diagnosis and monitoring of Parkinson’s disease and other neurodegenerative disorders.

“Broadening access to 18F-FP-CIT across these regions strengthens diagnostic capacity for neurodegenerative disease, enhances our manufacturing footprint, and delivers wider access to both patients and healthcare providers,” Cyclotek CEO Greg Santamaria.

DuChemBio CEO Kim Sang-woo also said, “This partnership marks a turning point for the global expansion of 18F-FP-CIT, extending DuChemBio’s presence from China, Taiwan, Australia, and New Zealand into India and Southeast Asia.”

The company also plans to accelerate its expansion into therapeutic radiopharmaceuticals, Kim added.